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Background
KS is the most common cancer in people with HIV/
AIDS, affecting both men and women in sub-Saharan
Africa. Without HAART, mortality is high. Given poor
access to HAART and prevalent HIV and KS-associated
herpesvirus co-infection, advanced HIV-KS is an
increasing problem in KZN. This is the first prospective
study evaluating the impact of HAART and the role of
early chemotherapy in HIV-KS in Africa.
Methods
We performed a randomized, controlled, open-label trial
comparing HAART to the combination of HAART and
chemotherapy (CXT) in treatment-naive patients with
biopsy-confirmed HIV-KS, recruited from the dermatol-
ogy clinic at King Edward VIII Hospital, KZN, South
Africa. Patients were stratified by ACTG risk group.
HAART was stavudine, lamivudine, and nevirapine.
CXT consisted of HAART plus bleomycin (10 U/m
2),
doxorubicin (20 mg/m
3), and vincristine (1.4 mg/m
2).
Responses were evaluated by ACTG criteria. We per-
formed an intention-to-treat comparison between arms
of KS clinical responses at month 12 (Fisher exact test),
rate of response (Mantel-Haenszel rate ratio), and over-
all survival (log-rank test). ACTG prognostic criteria
were evaluated (Cox proportional hazard regression).
Toxicity was monitored using DAIDS criteria. Adher-
ence was assessed by a 7-day recall questionnaire. Toxi-
cities, adherence, and changes in CD4 and HIV-1 viral
load were compared between arms (Fisher exact test).
Results
Baseline characteristic: 310 patients were screened, with
112 (62 women, 50 men) randomized; 59 to HAART
and 53 to CXT arm. Mean age 34 (20-63 yrs). 89% had
advanced disease (T1 disease), 93% poor risk by ACTG
criteria, 58% with CD4 <200, 42% had a history of co-
morbid infection; commonly tuberculosis (34%).
Responses: The overall response rate (complete
responses plus partial responses) at month 12 was 39%
in the HAART arm and 66% in the CXT arm (p=0.005).
T h eC X Ta r mh a da2 . 7t i m e sf a s t e rr e s p o n s er a t e
(p<0.001). Overall survival at 12 months was 76%, with
no significant differences between arms (p=0.49). ACTG
TIS staging was validated (p=0.03), with systemic illness
the most significant prognosticator of overall survival.
There were no significant differences in CD4 improve-
ment, HIV viral load decay, adverse events, or adherence
between arms.
Conclusion
HAART dramatically improves overall survival in Afri-
can patients with HIV-KS compared to historic controls.
Addition of chemotherapy improves response rates in
patients with advanced (T1) HIV-KS.
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